Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
68
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments


- In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed.

- Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.

- Quantum BioPharma’s Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2.

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate: Lucid-MS.

Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Global prevalence rose from about 2.3 million people in 2013 to roughly 2.8 million in 2020 and had climbed to an estimated 2.9 million by 2023.

In the United States alone, close to one million people are living with the disease. A landmark study published in the journal “Neurology” found the figure was more than double what had previously been assumed for decades. The disease typically strikes people in their 20s and 30s, with women being diagnosed at roughly twice the rate of men.

The symptoms of MS can be unpredictable and wide ranging. They include fatigue, vision problems, numbness, balance and coordination trouble, and cognitive changes, all stemming from damaged communication between the brain and the rest of the body. Because the disease can progress differently in every patient, diagnosis and treatment planning remain genuinely difficult for physicians.

Most currently available therapies fall into a category called disease-modifying therapies, and the majority of these treatments work by suppressing or modulating the immune system. Interferons, glatiramer acetate and newer monoclonal antibodies are among the most widely prescribed options, and research shows these drugs can meaningfully reduce relapse rates for people with relapsing forms of the disease.

But that same body of research points to real limitations. Injectable immunomodulatory therapies suffer from poor long-term adherence, with roughly half of patients discontinuing treatment within the first year, according to the same published review. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.

That gap between managing relapses and actually protecting nerve tissue is where newer approaches are working to make progress. Researchers are increasingly interested in neuroprotective and remyelinating strategies, ones that aim to preserve or restore the myelin sheath itself rather than only calming the immune system’s attack on it.

Quantum BioPharma’s Lucid-MS candidate fits into that emerging category. Rather than suppressing immune activity, the compound is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2, which when overactive has been linked to myelin breakdown. Quantum reports that in preclinical animal studies, the compound prevented myelin degradation, and findings from that research have appeared in peer-reviewed outlets, including the Journal of Medicinal Chemistry and Proceedings of the National Academy Sciences.

The company recently reached a significant milestone in its efforts. The FDA cleared Quantum BioPharma’s Investigational New Drug (“IND”) application for Lucid-MS, allowing the company to move the candidate into phase 2 clinical trials. That stage of testing is designed to evaluate whether the drug is effective in treating MS in a controlled patient population and also allows for continued safety monitoring.

The global market for MS therapeutics reflects just how much is riding on finding better options. Precedence Research estimates that market at approximately $34.8 billion in 2025, with projections suggesting it could nearly double by 2035 as new mechanisms of action reach patients.

For the millions of people currently living with multiple sclerosis, and the hundreds of thousands more diagnosed each year, incremental progress in the lab eventually has to translate into new choices at the pharmacy. Quantum BioPharma is one of several companies working toward that goal, betting that protecting nerve tissue directly, rather than only quieting the immune system, could open a new chapter in how the disease is treated.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

Quantum Biopharma Ltd. (QNTM) Stock Research Links

QNTM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 138

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 16

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Miami Office Puts Dubai Closer to U.S. Business Deal Flow

Updated Category News Views 68

Miami is not a random pin on a map; it is a deliberate front door to the Americas, and Dubai International Chamber has decided it needs someone standing in it. The chamber opened a representative office there on November 19, 2026, its second in the United States after launching in New York during the Dubai Business Forum – USA in November 2025. This is not the sort of...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 144

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 53

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 102

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Unveils New Wealth Management Tools for Advisors

Updated Category News Views 212

Orion Unveils New Wealth Management Tools for Advisors Orion, known for empowering financial advisors with cutting-edge wealth management solutions, is excited to announce a series of significant enhancements aimed at assisting advisors in servicing high-net-worth (HNW) and ultra-high-net-worth (UHNW) clientele. As new economic paradigms shift with generational wealth...

Continue Reading
Myriad Genetics Enhances Breast Cancer Research with Collaborations

Updated Category News Views 119

Myriad Genetics Expands Research Collaborations for Breast Cancer Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s...

Continue Reading
Man Group PLC Discloses Significant Position in American Axle

Updated Category News Views 158

Significant Position Disclosure by Man Group PLC Man Group PLC, a global investment management firm, has made a notable disclosure concerning its significant interests in American Axle & Manufacturing Holdings, Inc. This disclosure falls under Rule 8.3 of the UK Takeover Code, which mandates disclosure by entities holding 1% or more of relevant securities in any company...

Continue Reading
Legal Protection Steps for Jasper Therapeutics Investors

Updated Category News Views 223

Understanding the Importance of Legal Counsel Deciding to invest in a company like Jasper Therapeutics, Inc. (NASDAQ: JSPR) can be a significant move, but it's crucial to be aware of the potential challenges that come with investing in securities. Individuals who have bought shares in Jasper Therapeutics between certain dates should pay close attention to upcoming...

Continue Reading
TotalEnergies Expands on Gas Strategy with Latest Acquisition

Updated Category News Views 124

TotalEnergies Expands on Gas Strategy with Latest Acquisition TotalEnergies SE (TTE) shares have shown an upward trend, particularly in premarket trading. Recently, the company announced a notable agreement with Lewis Energy Group that involves acquiring a significant 45% stake in its dry gas-producing assets located in the Eagle Ford Basin, Texas. Details of the...

Continue Reading